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MiR-7 inhibits progression 
of hepatocarcinoma by targeting KLF-4 
and promises a novel diagnostic biomarker
Weizhong Wu1, Sanguang Liu2*, Yunfei Liang2, Zegao Zhou2 and Xueqing Liu2
Abstract 
Background: MicroRNAs are 22–24 nt non-coding RNAs that bind to the 3′ UTR of target mRNAs, thereby inducing 
mRNA degradation or inhibiting mRNA translation. Due to their implication in the regulation of post-transcriptional 
processes, the role of miRNAs in hepatocellular carcinoma (HCC) has been extensively studied. However, the function 
of miR-7 in HCC remains to be demonstrated.
Methods: 50 paired HCC tissues and matched peritumor tissues from patients were collected. The mRNA level of 
miR-7 was detected by qRT-PCR. The protein level of Kruppel-like factor 4 (KLF-4) was determined by western blot. Cell 
proliferation and invasive ability were measured using MTT and transwell invasion assay, respectively.
Results: We demonstrated that miR-7 was downregulated in 50 HCC tissues and the low expression of miR-7 was 
significantly correlate with tumour size. Moreover, overexpression of miR-7 significantly inhibited the proliferation and 
invasion of HCC cells. Over 100 target genes of miR-7 were predicted by Targetscan, and KLF-4 was indicated as the 
most promising candidate. Luciferase report assay showed that KLF-4 could be silenced by miR-7, so as to restore the 
impairment of cell proliferation and invasion in HCC cells.
Conclusions: In summary, we revealed a role of miR-7-KLF-4 axis in HCC cells, and the combination of both biomark-
ers might improve HCC diagnosis.
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Background
Hepatocellular carcinoma (HCC) is the fifth highest 
incidence rate of malignant tumor and the third lead-
ing cause of cancer-related death in the world [1]. The 
genetic or epigenetic regulations contributing to HCC 
have been well-characterized; however, the molecular 
mechanisms underlying pathogenesis still need to be 
defined [2]. MicroRNAs (miRNAs) are a class of small, 
non-coding RNAs, which modulate gene expression at 
the post-transcriptional level [3, 4]. A number of litera-
tures reported that the aberrant expression of miRNAs is 
a significant feature in various cancers [5, 6]. Functional 
studies have indicated that miRNAs play diverse roles in 
tumorigenesis, such as tumor suppressors or oncogenes, 
and act as modulators for tumor cell survival, apoptosis, 
and metastasis [7]. MiR-7 is an ancient miRNA, whose 
mature sequence is conserved from Annelida to human. 
Previous studies have implicated that miR-7 is involved 
in the development of different types of human cancers, 
including breast cancer [8] and HCC [9]. In these can-
cers, MiR-7 targets several proto-oncogenes, such as 
insulin receptor substrate 1 (IRS1), epidermal growth 
factor receptor (EGFR), and p21 protein (Cdc42/Rac)-
activated kinase 1 (PAK1) [10, 11]. In addition, Zhao et al. 
showed that miR-7 might function as a tumor suppressor, 
which inhibits cell growth and migration in non-small 
cell lung cancer cells [12, 13]. It has been reported that 
miR-7 was downregulated in HCC, but the regulatory 
mechanism in hepatoma cells remains unclear [14]. In 
the present study, we investigated the expression level of 
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miR-7 in HCC tissues and its pathways involved in HCC 




A total of 50 paired surgically resected HCC tissues and 
matched peritumor tissues were collected from patients 
during operation in our hospital (10 cases of T1N0M0, 13 
cases of T2N0M0, and 27 cases of T3N0M1). Exclusion 
criteria: HBV and HCV infection HCC patients. All tissues 
and tumor samples were flash-frozen in liquid nitrogen 
immediately after collection and stored at −80 °C for future 
use. This protocol was approved by the Ethics Committee 
of The Second Hospital of Hebei Medical University, and 
the written informed consents were obtained from all par-
ticipants prior to their participation in the study.
Cell culture and transfection
Hepatocellular carcinoma Hep3B, SMMC-7221, and 
HepG2 cell lines were purchased from ATCC (Manas-
sas, VA) and cultured in DMEM medium (Gibco, Grand 
Island, NY) supplemented with 10% heat-inactivated 
FBS, 100  U/mL penicillin, and 100  μg/mL streptomycin 
at 37  °C in a humidified chamber with 5% CO2. Scram-
bled control or miR-7 antagomir/mimic (ThermoFisher, 
Ambion) were transfected into cells with the Lipo-
fectamine 2000 reagent (Invitrogen, Carlsbad, CA), fol-
lowing the manufacturer’s instructions.
RNA isolation and quantitative RT‑PCR (qRT‑PCR)
Total miRNAs from liver tissues and cell lines were iso-
lated using mirVana™ miRNA isolation kit (Ambion, 
Austin, TX) following the manufacturer’s instructions. 
The expression levels of mature miR-7 and relative miR-
NAs were detected by qRT-PCR. A cDNA library was 
generated using M-MLV reverse transcriptase (Promega, 
Madison, WI) with specific RT-PCR primers. qPCR 
was performed using SYBR Premix EX Taq (TaKaRa, 
Otsu, Japan). The expression of miRNAs or mRNA was 
quantified by RT-PCR using 7500 Fast Real-Time PCR 
System (Applied Biosystems), and was normalized to 
U6B small nuclear RNA (RNU6B) or GAPDH. All sam-
ples were prepared and analyzed three times individu-
ally. Primers are as follows, GAPDH-F/R: 5′-TGAGT 
CAACACCTACCCAGCTCCAG-3′/5′-CAGAGTCAGT 
GATGGGGGGCTTG-3′; KLF4-F/R: 5′-GTCGGATTGA 
AGTGCTGAGC-3 ′/5 ′-ATCGTCTCTCTTCCCTT 
GGC-3′.
Western blot analysis of KLF‑4 expression
Western blot assays were performed as described previ-
ously [10]. Briefly, cells were lysed on ice in RIPA buffer 
(150  mM NaCl, 50  mM Tris pH 7.5, 1% TritonX-100, 
5  mM ethylenediaminetet–raacetic acid). After extrac-
tion of total protein, BCA Kit (Pierce, IL, USA) was used 
for protein concentration detection. Samples (30 μg) were 
separated by sodium dodecyl sulfate (SDS)-polyacryla-
mide gel electrophoresis (PAGE) and transferred onto 
nitrocellulose (NC) membranes. Membranes were incu-
bated with primary antibody KLF-4 (Santa Cruz Biotech, 
Santa Cruz, CA) at 4 °C overnight, followed by secondary 
antibody (Santa Cruz Biotech, Santa Cruz, CA). GAPDH 
(Cell Signaling Technology, Boston, USA) was used as a 
loading control. The Fusion FX7 system (VilberLourmat, 
France) was used for protein band visualization.
Luciferase reporter assay
In order to check the relationship between miR-7 and 
KLF-4, fragments of 3′-UTR (Wt) containing the bind-
ing site of miR-7, or 3′-UTR mutant (Mut) of KLF-4 were 
cloned into the pMIR-Report luciferase vector. SMMC-
7221 cells were cotransfected with luciferase reporter 
vector, Renilla luciferase control vector (pRL-hTK) and 
miR-7 mimics or the negative control miRNA, using 
Lipofectamine 2000 (Invitrogen). Luciferase assays were 
performed 48  h post-transfection using the dual-lucif-
erase reporter assay system (Promega). Firefly luciferase 
activity was normalized to Renilla luciferase activity.
MTT assay
24  h after transfection, Hep3B and SMMC-7221 cells 
were seeded into 96-well plates. The viability of the 
cells were evaluated by 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyl-tetrazolium bromide (MTT) assays according 
to the literature [15].
Matrigel invasion assay
50,000 labeled cells (using Cell tracker green, Invitrogen) 
were seeded into Matrigel-coated Transwell insert (Corning) 
in DMEM with 10% serum. The bottom side of transwell was 
filled with DMEM containing 20% serum. After 24 h, labeled 
cells were counted under a fluorescent microscope.
Statistical analysis
SPSS software (version 20.0) was used for all statistical 
calculations. Values were presented as mean ± standard 
deviation (SD). All experiments were repeated at least 
three times, and comparisons between two means were 
determined by the paired Student’s t test. Statistical sig-
nificance was established at P value less than 0.05.
Results
MiR‑7 is downregulated in HCC tissues
To evaluate whether miR-7 is aberrantly expressed in 
HCC tumor tissues, the expression of miR-7 in HCC 
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tumor tissues and matched peritumor tissues obtained 
from 50 patients was determined using qRT-PCR. 
The miR-7 expression in tumor tissues is significantly 
lower than that of the matched control (0.18 ±  0.04 vs. 
0.95  ±  0.07, P  =  0.0028, Fig.  1), indicating that miR-7 
may be a tumor suppressor in HCC. The miR-7 expres-
sion levels were classified to either low or high according 
to the median value of the cohort. The statistical analysis 
revealed a significant association between the low expres-
sion of miR-7 and tumour size (P = 0.0124) (Table 1).
MiR‑7 inhibits the proliferation and invasion of HCC cells
In order to check the inhibitory effect of miR-7 on cell 
proliferation and invasion of HCC cells, we first deter-
mined the expression level of miR-7 in HepG2, Hep3B 
and SMMC-7221 cell lines by qRT-PCR. As shown in 
Fig.  2, Hep3B cells displayed significantly higher miR-7 
expression level as compared with SMMC-7221 and 
HepG2 cells.
For comparison, overexpression of miR-7 mimics of 
SMMC-7221 cells and overexpression of miR-7 antago-
mirs Hep3B cells were established. After transfecting 
miR-7-antisense into Hep3B cells, the miR-7 expression 
level was dramatic decreased compared with the nega-
tive control (treated with the same length of RNA, with-
out any bioactivity) (Fig. 3a). The results from MTT assay 
showed that the miR-7-antisense-transfected Hep3B cells 
exhibited faster cell growth rate than the control cells 
(Fig.  3b). The matrigel invasion assay showed a higher 
invasive rate in miR-7-antisense-transfected Hep3B cells 
compared with the control cells (Fig.  3c). In contrast, 
SMMC-7221 transfected with miR-7 mimics showed an 
increased miR-7 expression (Fig. 3d) and a decreased cell 
growth (Fig. 3e) and invasion (Fig. 3f ), compared with the 
control cells. Together, these results suggested that miR-7 
inhibits cell proliferation and invasion of HCC cells.
The interaction between KLF‑4 and miR‑7 in HCC
MiRNAs function via suppressing or degrading the seg-
ments mRNA of target genes. In order to indentify the 
target genes interacted with miR-7, TargetScan 7.0 was 
employed for the prediction. A list of candidate targets 
of miR-7 were obtained, and among them, KLF-4 appears 
to be a promising target as it is implicated in the pathol-
ogy of cancer. Therefore, we the protein level of KLF-4 
in miR-7-silenced Hep3B cells. The results showed that 
the expression level of KLF-4 was significantly decreased 
in SMMC-7221 cells transfected with miR-7 mimics 
(Fig.  4a), whereas KLF-4 protein expression level in the 
miR-7-silenced Hep3B cells was significantly increased 
compared with the control cells (Fig.  4b). These results 
indicated that KLF-4 is a potential target of miR-7. To 
further validate this assumption, luciferase reporter 
assay was performed to analyze the relationship between 
KLF-4 and miR-7 in HCC cells. The results showed that 
miR-7 mimics significantly decreased the luciferase 
activity of KLF-4 3′-UTR, but had little effect on KLF-4 
3′-UTR mutant (Fig. 5b), confirming that KLF-4 is a tar-
get of miR-7. Moreover, we observed a statistically signif-
icant inversed correlation between miR-7 and KLF-4 in 
HCC samples (Fig. 6).
MiR‑7 regulates KFL‑4/PI3K/Akt pathway
PI3K/Akt pathway plays critical roles in tumorigenesis 
and cancer development. Therefore, we sought to exam-
ine if miR-7 has impact on this pathway. In miR-7 over-
expressing SMMC-7221 cells, we observed a significant 
decrease of KLF-4 expression, companied with a sig-
nificant reduction of AKT phosphorylation and mTOR 
expression (Fig. 7). This result indicated that miR-7 regu-
lates the KFL4/PI3K/Akt pathway.
Discussion
In this study, we found that miR-7 was downregulated in 
clinical samples, and the low expression of miR-7 showed 
a significant association with tumor size, suggesting an 
importance role of miR-7 in HCC tumorigenesis.
Targets of cancer-related miRNAs and their roles in 
tumorigenesis are needed to be fully understood [16]. 
Recently, it was reported that there were two ways for 
miRNAs to work. One way is to prevent translation, and 
the other one is to promote the degradation of specific 
target mRNAs by binding to their 3′ UTRs [17]. However, 
Fig. 1 Analysis of miR-7 expression in hepatocellular carcinoma 
(HCC) tissues and matched peritumor tissues by qRT-PCR. HCC tumor 
tissues displayed significantly lower miR-7 expression level than the 
matched peritumor tissues. **P < 0.01 vs. peritumor tissues
Page 4 of 7Wu et al. Cancer Cell Int  (2017) 17:31 
a novel assortment of research has demonstrated that 
miRNAs can function to post-transcriptionally stimu-
late gene expression through direct mechanisms, and 
this process is termed “activation” [18]. MiR-7 is highly 
expressed in parts of the brain, eyes, and pancreas, sug-
gesting its role in the development of these organs. Stud-
ies showed that in glioblastomas and breast cancer, the 
expression of miR-7 was aberrant. Many potential targets 
of miR-7 were reported to participate in some important 
signalling of tumor progression, such as targets EGFR, 
IRS-1, PAK-1, RAF-1, SATB1, and so on [11, 19]. In this 
study, results showed that KLF4 was a critical down-
stream target of miR-7 in HCC. Moreover, we found a 
predicted miR-7 binding site on the KLF-4 transcript 
and results from the luciferase reporter assay confirmed 
the interaction between miR-7 and KLF-4. Meanwhile, 
results of Western blot demonstrated that miR-7 nega-
tively regulated KLF-4 expression. Previous report has 
shown that miR-7 abrogates KLF4/PI3K/Akt pathway 
and inhibits prostate tumorigenesis [20]. In this study, 
we also found miR-7 could inhibit cell proliferation and 
Table 1 Association between miR-7 expression and clinicopathologic characteristics
The statistical significance of the individuals was determined with χ2 test. P < 0.05 was considered significant
Features n (%) High expression (%) Low expression (%) P/χ2 value
Gender 0.879/0.023
 Male 27 (77.6) 13 (67.8) 14 (32.2)
 Female 23 (22.4) 10 (45.7) 13 (54.3)
Age (year) 0.653/0.365
 ≥60 23 (62.2) 14 (60.8) 9 (39.2)
 <60 27 (37.8) 13 (55.9) 14 (44.1)
Tumor size (mm) 0.012/10.054
 ≥50 28 (71.8) 8 (71.4) 20 (28.6)
 <50 22 (28.2) 14 (81.8) 8 (18.2)
AFP (ng/mL) 0.275/1.256
 >400 23 (49.4) 9 (45.5) 14 (54.5)
 <400 27 (50.6) 13 (40.5) 14 (59.5)
TNM stage 0.027/12.864
 T1 16 (35.9) 11 (39.3) 5 (60.7)
 T2/T3 34 (64.1) 16 (46.0) 18 (54.0)
Intrahepatic metastasis status 0.019/1.358
 Positive 15 (30.0) 12 (80.0) 3 (20.0)
 Negative 35 (70.0) 18 (51.4) 17 (48.6)
Tumor number
 Single 32 (64.0) 14 (43.8) 18 (56.2) 0.504/9.281
 Two or more 18 (36.0) 8 (44.4) 10 (55.6)
Fig. 2 Analysis of miR-7 expression levels in different HCC cell lines 
by qRT-PCR
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Fig. 3 Cell proliferation and invasion of HCC cells detected by MTT assay and matrigel invasion assay, respectively. a Expression levels of miR-7 
were detected in Hep3B cells transfected with miR-7 antisense or NCi; b relative growth rate of Hep3B cells transfected with miR-7 antisense or 
NCi; c invaded cells per field Hep3B cells transfected with miR-7 antisense or NCi; d expression levels of miR-7 were detected in SMMC-7221 cells 
transfected with miR-7 mimics or NCi; e relative growth rate of SMMC-7221 cells transfected with miR-7 antisense or NCi; f invaded cells per field in 
SMMC-7221 cells transfected with miR-7 antisense or NC
Fig. 4 Expression of KLF-4 protein level in miR-7 silenced Hep3B cells detected by Western blot. a Expression level of miR-7 was detected in SMMC-
7221 cells transfected with miR-7 mimics or NC; b expression level of KLF-4 protein was detected in Hep3B cells transfected with miR-7 antisense or 
NC
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invasion of HCC. Moreover, overexpression of miR-7 sig-
nificantly suppressed the expression of KLF4, as well as 
the phosphorylation and expression of PI3K/Akt pathway 
downstream effectors.
Conclusions
In summary, we revealed a close relationship between 
miR-7 and KLF-4. Our results showed that the low 
expression of miR-7 was significantly associated with 
tumour size, indicating that it might serve as an inde-
pendent prognostic factor for HCC disease. We also 
identified that KLF-4 is a target of miR-7 in HCC cells. 
This newly identified target KLF-4 of miR-7 may be con-
sidered as a potential prognostic marker and a therapeu-
tic target for HCC patients.
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